Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia
Lars Rejnmark, Line Underbjerg · 2026
Read Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia by Lars Rejnmark, Line Underbjerg (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13659921.txt.
Description
Lars Rejnmark and Line Underbjerg report what happened when a woman with chronic hypoparathyroidism stopped a long-acting hormone replacement drug. Her parathyroid glands had failed after thyroid surgery, leaving her unable to keep blood calcium steady. She had taken palopegteriparatide for more than four years. Earlier reports warned that stopping such therapy can trigger a hungry bone state, with calcium crashing and supplement needs soaring.
In her case, none of that happened. She returned to ordinary calcium and active vitamin D at doses much like those she used before the drug, and her vitamin D dose was later lowered because calcium ran high-normal. She stayed well, with normal calcium values through follow-up and no symptoms. The authors suggest some patients can safely move back to standard therapy after long treatment.
Catalog record
| CREATOR | Lars Rejnmark, Line Underbjerg |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |